The potential of Fas ligand (apoptosis-inducing molecule) as an unconventional therapeutic target in type 1 diabetes

Frontiers in Immunology

Volumn 3, Issue JUL, 2012, Pages

  Hamad, Abdel Rahim A R ^a   Arcara, Kristin ^a   Uddin, Sophia ^a   Donner, Thomas ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Autoimmune diabetes; Fas pathway; Immunosuppression; Immunotherapy; Lymphoproliferative disorders

Indexed keywords

EID: 84874211304     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00196     Document Type: Article

References (66)

1. Apostolou, I., Hao, Z., Rajewsky, K., and von Boehmer, H. (2003). Effective destruction of Fas-deficient insulin-producing beta cells in type 1 diabetes.J Exp. Med. 198, 1103-1106.
2. Atkinson, M. A., Bluestone, J. A., Eisen-barth, G. S., Hebrok, M., Herold, K. C, Accili, D., Pietropaolo, M., Arvan, P. R., Von Herrath, M., Markel, D. S., and Rhodes, C. J. (2011). How does type 1 diabetes develop?: the notion of homicide or beta-cell suicide revisited. Diabetes 60, 1370-1379.
3. Bluestone, J. A. (2011). The yin and yang of interleukin-2-mediated immunotherapy. N. Engl. J. Med. 365, 2129-2131.
4. Bluestone, J. A., Herold, K., and Eisenbarth, G. (2010). Genetics, pathogen-esis and clinical interventions in type 1 diabetes. Nature 464,1293-1300.
5. Bolt, S., Routledge, E., Lloyd, I., Chatenoud, L., Pope, H., Gorman, S. D., Clark, M., and Waldmann, H. (1993). The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur.]. Immunol. 23,403-411.
6. Bouillet, P., and O'Reilly, L. A. (2009). CD95, BIM and T cell homeostasis. Nat. Rev. Immunol. 9, 514-519.
7. Brunner, T., Mog, R., LaFace, D., Yoo, N., Mahboubl, A., Echeverri, F., Martin, S., Force, W., Lynch, D., Ware, C, and Green, D. (1995). Cell autonomous Fas (CD95)/Fas lig-and interaction mediates activation induced apoptosis in T cell hybrido-mas. Nature 373, 441-444.
8. Bulek, A. M., Cole, D. K., Skowera, A., Dolton, G., Gras, S., Madura, F., Fuller, A., Miles, J. J., Gostick, E., Price, D. A., Drijfhout, J. W., Knight, R. R., Huang, G. C, Lissin, N., Mol-loy, P. E., Wooldridge, L., Jakobsen, B. K., Rossjohn, J., Peakman, M., Rizkallah, P. J., and Sewell, A. K. (2012). Structural basis for the killing of human beta cells by CD8(+)Tcells in type 1 diabetes. Nat. Immunol. 13, 283-289.
9. Chervonsky, A. V., Wang, Y., Wong, F. S., Visintin, I., Flavell, R. A., Janeway, C. A. Jr., and Matis, L. A. (1997). The role of Fas in autoimmune diabetes. Cell 89, 17-24.
10. Cohen, P., and Eisenberg, R. (1991). Lpr and gld: single gene models of systemic autoimmunity and lym-phoproliferative disease. Annu. Rev. Immunol. 9,243-269.
11. Coppieters, K. T., Dotta, E, Amirian, N., Campbell, P. D., Kay, T. W, Atkinson, M. A., Roep, B. O., and von Herrath, M. G. (2012). Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients.J Exp. Med. 209, 51-60.
12. Dahlquist, G. G., Nystrom, L., and Patterson, C. C. (2011). Incidence of type 1 diabetes in Sweden among individuals aged 0-34 years, 19832007: an analysis of time trends. Diabetes Care 34,1754-1759.
13. Denault, J. B., and Salvesen, G. S. (2002). Caspases. Curr. Protoc. Protein Sri. Chapter 21, Unit 21 28.
14. Dhein, J., Walczack, H., Baumler, C, Debatin, K.-M., and Krammer, P. (1995). Autocrine T cell suicide mediated by APO-1 (Fas/CD95). Nature 373,438-441.
15. Gillette-Ferguson, I., and Sidman, C. L. (1994). A specific intercellular pathway of apoptotic cell death is defective in the mature peripheral T cells of autoimmune lpr and gld mice. Eur. J.Immunol. 24,1181-1185.
16. Gonzalo, J. A., Tarazona, R., Schuurman, H. J., Uytdehaag, E, Wick, G., Martinez, C, and Kroemer, G. (1994). A single injection of Staphylococcus aureus enterotoxin B reduces autoimmunity in MRL/lpr mice. Clin. Immunol. Immunopathol. 71,176-182.
17. Grinberg-Bleyer, Y., Baeyens, A., You, S., Elhage, R., Fourcade, G., Gregoire, S., Cagnard, N., Carpentier, W., Tang, Q., Bluestone, J., Chatenoud, L., Klatzmann, D., Salomon, B. L., and Piaggio, E. (2010). IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells.J Exp. Med. 207, 1871-1878.
18. Hamad, A. R. (2010). Analysis of gene profile, steady state proliferation and apoptosis of double-negative T cells in the periphery and gut epithelium provides new insights into the biological functions of the Fas pathway. Immunol. Res. 47,134-142.
19. Harjutsalo, V., Forsblom, C, and Groop, P. H. (2011). Time trends in mortality in patients with type 1 diabetes: nationwide population based cohort study. BMJ 343, d5364.
20. Henriques-Pons, A., and de Oliveira, G. M. (2009). Is the Fas/Fas-L pathway a promising target for treating inflammatory heart disease?J Cardiovasc. Pharmacol. 53, 94-99.
21. Herold, K. C, Gitelman, S. E., Masharani, U., Hagopian, W., Bisikirska, B., Donaldson, D., Rother, K., Diamond, B., Harlan, D. M., and Blue-stone, J. A. (2005). A single course of anti-CD3 monoclonal antibody hOKT3gammal (Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54,1763-1769.
22. Hildeman, D. A., Zhu, Y., Mitchell, T. C, Bouillet, P., Strasser, A., Kap-pler, J., and Marrack, P. (2002). Activated T cell death in vivo mediated by proapoptotic bcl-2 family member bim. Immunity 16, 759-767.
23. Hughes, P. D., Belz, G. T., Fortner, K. A., Budd, R. C, Strasser, A., and Bouillet, P. (2008). Apoptosis regulators Fas and Bim cooperate in shutdown of chronic immune responses and prevention of autoimmunity. Immunity 28, 197-205.
24. Hutcheson, J., Scatizzi, J. C, Siddiqui, A. M., Haines, G. K. Ill, Wu, T., Li, Q. Z., Davis, L. S., Mohan, C, and Perlman, H. (2008). Combined deficiency of proapoptotic regulators Bim and Fas results in the early onset of systemic autoimmunity. Immunity 28,206-217.
25. Joslin, E. P. (1924). The treatment of diabetes mellitus. Can. Med. Assoc. J. 14,808-811.
26. Joslin, E. P. (1936). Insulin, old and new, in the treatment of diabetes. Can. Med. Assoc. J. 35,526-531.
27. Ju, S., Panks, D., Cul, H., Ettingor, R., Elkhatib, M., Sherr, D., Stanger, B., and Marshak-Rothstein, A. (1995). Fas (CD95)/FasL interactions required for programmed cell death after T cell activation. Nature 373, 444-448.
28. Keymeulen, B., Walter, M., Mathieu, C, Kaufman, L., Gorus, F., Hilbrands, R., Vandemeulebroucke, E., Van de Velde, U., Crenier, L, De Block, C, Candon, S., Waldmann, H., Ziegler, A. G., Chatenoud, L., and Pipeleers, D (2010). Four-year metabolic out come of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline resid ual beta cell mass. Diabetologia 53, 614-623.
29. Kim, Y. H., Kim, S., Kim, K. A., Yagita, H., Kayagaki, N., Kim, K. W., and Lee, M. S. (1999). Apoptosis of pancreatic beta-cells detected in accelerated diabetes of NOD mice: no role of Fas-Fas ligand interaction in autoimmune diabetes. Eur. J. Immunol. 29, 455-465.
30. Ko, G. J., Jang, H. R., Huang, Y, Womer, K. L., Liu, M., Higbee, E., Xiao, Z., Yagita, H., Racusen, L., Hamad, A. R., and Rabb, H. (2011). Blocking Fas ligand on leukocytes attenuates kidney ischemia-reperfusion injury.J Am. Soc. Nephrol. 22, 732-742.
31. Koreth, J., Matsuoka, K., Kim, H. T., McDonough, S. M., Bindra, B., Alyea, E. P. Ill, Armand, P., Cutler, C, Ho, V. T., Treister, N. S., Bienfang, D. C, Prasad, S., Tzachanis, D., Joyce, R. M., Avigan, D. E., Antin, J. H., Ritz, J., andSoiffer, R. J. (2011). Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 365, 2055-2066.
32. Kotzin, B. L., Babcock, S. K., and Herron, L. R. (1988). Deletion of potentially self-reactive T cell receptor specificities in L3T4-, Lyt-2T cells of lpr mice.J Exp. Med. 168, 2221-2229.
33. Lenardo, M. J. (1996). Fas and the art of lymphocyte maintenance.J Exp. Med. 183,721.
34. Lohman, B. L., Razvi, E. S., and Welsh, R. M. (1996). T-lymphocyte down-regulation after acute viral infection is not dependent on CD95 (Fas) receptor-ligand interactions.J Virol. 70,8199-8203.
35. Maldonado, M. A., Kakkanaiah, V., MacDonald, G. C, Chen, F., Reap, E. A., Balish, E., Farkas, W R., Jennette, J. C, Madaio, M. P., Kotzin, B. L., Cohen, P. L., and Eisenberg, R. A. (1999). The role of envi ronmental antigens in the sponta neous development of autoimmunity in MRL-lpr mice.J Immunol. 162, 6322-6330.
36. Marrack, P., and Kappler, J. (2004). Control of T cell viability. Annu. Rev. Immunol. 22, 765-787.
37. Miethke, T., Vabulas, R., Bittlingmaier, R., Heeg, K., and Wagner, H. (1996). Mechanisms of peripheral T cell deletion: anergized T cells are Fas resistant but undergo proliferation-associated apoptosis. Eur. J. Immunol. 26,1459-1467.
38. Mogil, R. J., Radvanyi, L., Gonzalez-Quintial, R., Miller, R., Mills, G., Theofilopoulos, A. N., and Green, D. R. (1995). Fas (CD95) participates in peripheral T cell deletion and associated apoptosis in vivo. Int. Immunol. 7,1451-1458.
39. Mohamood, A. S.,Bargatze,D.,Xiao, Z., Jie, C, Yagita, H., Ruben, D., Watson, J., Chakravarti, S., Schneck, J. P., and Hamad, A. R. (2008). Fas-mediated apoptosis regulates the composition of peripheral a(3 T cell repertoire by constitutively purging out double negative T cells. PLoS ONE 3, e3465. doi: 10.1371/journal.pone. 0003465
40. Mohamood, A. S., Guler, M. L., Xiao, Z., Zheng, D., Hess, A., Wang, Y, Yagita, H., Schneck, J. P., and Hamad, A. R. (2007). Protection from autoimmune diabetes and T-cell lymphoprolifera-tion induced by FasL mutation are differentially regulated and can be uncoupled pharmacologically. Am. J. Pathol. 171, 97-106.
41. Mountz, J. D., Smith, T. M., and Toth, K. S. (1990). Altered expression of self-reactive T cell receptor V beta regions in autoimmune mice.J Immunol. 144,2159-2166.
42. Nagata, S., and Golstein, P. (1995). The Fas death factor. Science 267, 1449-1456.
43. Nagata, S., and Suda, T. (1995). Fas and Fas ligand: lpr and gld mutations. Immunol. Today 16, 39-43.
44. Nakayama, M., Abiru, N., Moriyama, H., Babaya, N., Liu, E., Miao, D., Yu, L, Wegmann, D. R., Hutton, J. C, Elliott, J. E, and Eisenbarth, G. S. (2005). Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435, 220-223.
45. Nakayama, M., Nagata, M., Yasuda, H., Arisawa, K., Kotani, R., Yamada, K., Chowdhury, S. A., Chakrabarty, S., Jin, Z. Z., Yagita, H., Yokono, K., and Kasuga, M. (2002). Fas/Fas ligand interactions play an essential role in the initiation of murine autoimmune diabetes. Diabetes 51, 1391-1397.
46. Patterson, C. C, Dahlquist, G. G., Gyu-rus, E., Green, A., and Soltesz, G. (2009). Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 373,2027-2033.
47. Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. E, Moran, A. M., Raskin, P., Rodriguez, H., Schatz, D. A., Wherrett, D., Wilson, D. M., Lachin, J. M., and Skyler, J. S. (2009). Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 361, 2143-2152.
48. Petrovsky, N., Silva, D., Socha, L., Slat-tery, R., and Charlton, B. (2002). The role of Fas ligand in beta cell destruction in autoimmune diabetes of NOD mice. Ann. N Y. Acad. Sci. 958, 204-208.
49. Saadoun, D., Rosenzwajg, M., Joly, F., Six, A., Carrat, E, Thibault, V., Sene, D., Cacoub, P., and Klatzmann, D. (2011). Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl. J. Med. 365, 2067-2077.
50. Sherry, N., Hagopian, W, Ludvigsson, J., Jain, S. M., Warden, J., Ferry, R. J. Jr., Bode, B., Aronoff, S., Holland, C, Carlin, D., King, K. L, Wilder, R. L., Pillemer, S., Bonvini, E., Johnson, S., Stein, K. E., Koenig, S., Herold, K. C, and Daifotis, A. G. (2011). Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 378, 487-497.
51. Siegel, R. M., Frederiksen, J. K., Zacharias, D. A., Chan, F. K., Johnson, M., Lynch, D., Tsien, R. Y, and Lenardo, M. J. (2000). Fas preas-sociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 288, 2354-2357.
52. Singer, P. A., Balderas, R. S., McEvilly R. J., Bobardt, M., and Theofilopoulos, A. N. (1989). Tolerance-related V beta clonal deletions in normal CD4-8-, TCR-alpha/beta+ and abnormal lpr and gld cell populations.J Exp. Med. 170, 1869-1877.
53. Stranges, P. B., Watson, J., Cooper, C. J., Choisy-Rossi, C. M., Stonebraker, A. C, Beighton, R. A., Hartig, H., Sundberg, J. P., Servick, S., Kauf-mann, G., Fink, P. J., and Chervonsky, A. V. (2007). Elimination of antigen-presenting cells and autoreactive T cells by fas contributes to prevention of autoimmunity. Immunity 26, 629-641.
54. Strasser, A., Jost, P. J., and Nagata, S. (2009). The many roles of FAS receptor signaling in the immune system. Immunity 30,180-192.
55. Su, G., Blaine, S. A., Qiao, D., and Friedl, A. (2007). Shedding of syndecan-1 by stromal flbroblasts stimulates human breast cancer cell proliferation via FGF2 activation.J Biol Chem. 282, 14906-14915.
56. Su, X., Hu, Q., Kristan, J. M., Costa, C, Shen, Y., Gero, D., Matis, L. A., and Wang, Y. (2000). Significant role for Fas in the pathogenesis of autoimmune diabetes.J Immunol. 164,2523-2532.
57. Suzuki, I., Martin, S., Boursalian, T. E., Beers, C, and Fink, P. J. (2000). Fas ligand costimulates the in vivo proliferation of CD8+ T cells.J Immunol. 165,5537-5543.
58. Tang, Q., Adams, J. Y, Penaranda, C, Melli, K., Piaggio, E., Sgouroudis, E., Piccirillo, C. A., Salomon, B. L., and Bluestone, J. A. (2008). Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28, 687-697.
59. The Diabetes Control and Complications Trial Research Group. (1998). Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann. Intern. Med. 128,517-523.
60. van Belle, T. L., Coppieters, K. T., and von Herrath, M. G. (2011). Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol. Rev. 91,79-118.
61. Waldner, H., Sobel, R. A., Howard, E., and Kuchroo, V. K. (1997). Fas-and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis.J Immunol. 159, 3100-3103.
62. Watanabe-Fukunaga, R., Brannan, C, Copeland, N., Jenkins, N., and Nagata. S. (1992). Lymphoprolifer-ation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356, 314-317.
63. Weant, A. E., Michalek, R. D., Khan, I. U., Holbrook, B. C, Willingham, M. C, and Grayson, J. M. (2008). Apop tosis regulators Bim and Fas function concurrently to control autoimmu nity and CD8+ T cell contraction. Immunity 28, 218-230.
64. Wenzlau, J. M., Frisch, L. M., Gardner, T. J., Sarkar, S., Hutton, J. C, and Davidson, H. W. (2009). Novel antigens in type 1 diabetes: the importance of ZnT8. Curr. Diab. Rep. 9,105-112.
65. Yu, L., Herold, K., Krause-Steinrauf, H., McGee, P. L., Bundy, B., Pugliese, A., Krischer, J., and Eisenbarth, G. S. (2011). Rituximab selectively suppresses specific islet antibodies. Diabetes 60,2560-2565.
66. Zhou, T., Bluethmann, H., Zhang, J., Edwards, C. K. Ill, and Mountz, J. D. (1992). Defective maintenance of T cell tolerance to a superantigen in MRL-lpr/lpr mice.J Exp. Med. 176, 1063-1072.